Information Provided By: 
Fly News Breaks for April 25, 2018
KPTI
Apr 25, 2018 | 07:23 EDT
Cantor Fitzgerald analyst Mara Goldstein expects Karyopharm Therapeutics to report results of the Phase IIb Storm study in multiple myeloma by the end of April. If positive, that should enable the company to submit a new drug application for selinexor under the accelerated approval mechanism, Goldstein tells investors in a research note. The analyst thinks a positive readout, consistent with data generated thus far, could propel the shares to the $21-$25 level. Goldstein reiterates an Overweight rating on Karyopharm with an $18 price target.
News For KPTI From the Last 2 Days
There are no results for your query KPTI
